BFC Planning’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$142K Buy
577
+447
+344% +$114K 0.01% 1076
2026
Q2
$39.1K Sell
130
-10
-7% -$3.02K ﹤0.01% 1674
2026
Q1
$46.3K Buy
140
+89
+175% +$30.3K ﹤0.01% 1367
2025
Q4
$20.3K Sell
51
-1
-2% -$443 ﹤0.01% 1752
2025
Q3
$23.7K Sell
52
-10
-16% -$4.07K ﹤0.01% 1497
2025
Q2
$20.2K Buy
62
+15
+32% +$4.15K ﹤0.01% 1495
2025
Q1
$12.7K Buy
47
+41
+683% +$10.5K ﹤0.01% 1662
2024
Q4
$1.41K Hold
6
– – ﹤0.01% 2352
2024
Q3
$1.65K Buy
+6
New +$1.56K ﹤0.01% 2317

Other funds holding ALNY

BFC Planning's ALNY Position: Q3 2026 in Review

BFC Planning increased its Alnylam Pharmaceuticals (ALNY) stake by 344% in Q3 2026, buying an estimated $114K and bringing the position to 577 shares worth $142K. The position accounts for 0.01% of the portfolio, ranked #1076.

BFC Planning first reported a position in ALNY in Q3 2024 and has held it in 9 quarters since. 604 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • BFC Planning held 577 shares of Alnylam Pharmaceuticals worth $142K as of Q3 2026.
  • BFC Planning bought 447 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $114K.
  • Alnylam Pharmaceuticals made up 0.01% of BFC Planning's portfolio in Q3 2026, its #1076 holding.
  • BFC Planning first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
  • 604 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.